ICU · Respiratory
Acute severe pneumonia: source control and pleural complications
Also known as Pneumonia source control · Lung abscess · Empyema drainage · Bronchopleural fistula
Source control in pneumonia means draining or removing infected material. Pleural complications: (1) Parapneumonic effusion (simple/complicated/empyema). (2) Lung abscess. (3) Bronchopleural fistula. Management: parapneumonic effusion (low-risk: observe/antibiotics; complicated/empyema: image-guided chest drain + antibiotics; loculated: intrapleural tPA + DNase, early surgical review if failing). Lung abscess: prolonged antibiotics (median 38 days in a contemporary cohort; courses under 6 weeks carry worse outcomes) with percutaneous drainage when antibiotics fail. Bronchopleural fistula: chest tube + surgical or endobronchial repair. Source control is essential — drainage of infected fluid is key to successful treatment.
Checked against its sources on 14 Oct 2026
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Pleural fluid pH under 7.2 with signs of infection defined pleural infection in the MIST1 trial — these collections need drainage, not antibiotics alone
- Lung abscess: prolonged antibiotics — median 38 days in a contemporary cohort; courses shorter than 6 weeks were associated with worse outcomes
- Bronchopleural fistula: persistent air leak in the chest drain means communication between bronchus and pleural space
- Empyema not draining despite chest tube: intrapleural tPA 10 mg + DNase 5 mg twice daily for 3 days (MIST2 regimen) — neither agent alone works; involve surgery early
Meet the patient
An older man with severe aspiration pneumonia remains febrile and shocked after broad-spectrum antibiotics. Ultrasound shows a septated pleural collection; the drain yields only a small amount of thick pus.[5]
The ward-round question is not “which antibiotic next?” It is “where is the infected material, and how will you remove it?” Antibiotics are necessary, but a closed collection needs a route out — more than 30% of patients with pleural infection either die or require surgery.[2]
References20ShowHide
- [1]Niederman MS, Torres A Severe community-acquired pneumonia Eur Respir Rev, 2022.PMID 36517046
- [2]Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection N Engl J Med, 2011.PMID 21830966
- [3]Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection N Engl J Med, 2005.PMID 15745977
- [4]Popowicz N, Bintcliffe O, De Fonseka D, et al. Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project Ann Am Thorac Soc, 2017.PMID 28324671
- [5]Bedawi EO, Ricciardi S, Hassan M, et al. ERS/ESTS statement on the management of pleural infection in adults Eur Respir J, 2023.PMID 36229045
- [6]Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline Chest, 2000.PMID 11035692
- [7]Mei F, Rota M, Bonifazi M, et al. Efficacy of Small versus Large-Bore Chest Drain in Pleural Infection: A Systematic Review and Meta-Analysis Respiration, 2023.PMID 36693327
- [8]Corcoran JP, Psallidas I, Gerry S, et al. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study Eur Respir J, 2020.PMID 32675200
- [9]Lois M, Noppen M Bronchopleural fistulas: an overview of the problem with special focus on endoscopic management Chest, 2005.PMID 16354867
- [10]Hadid W, Stella GM, Maskey AP, et al. Lung abscess: the non-conservative management: a narrative review J Thorac Dis, 2024.PMID 38883669
- [11]Lee JH, Hong H, Tamburrini M, et al. Percutaneous transthoracic catheter drainage for lung abscess: a systematic review and meta-analysis Eur Radiol, 2022.PMID 34327579
- [12]Vaarst JK, Sperling S, Dahl VN, et al. Lung abscess: Clinical characteristics of 222 Danish patients diagnosed from 2016 to 2021 Respir Med, 2023.PMID 37302422
- [13]Maitre T, Ok V, Calin R, et al. Pyogenic lung abscess in an infectious disease unit: a 20-year retrospective study Ther Adv Respir Dis, 2021.PMID 34098822
- [14]Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis JAMA, 2012.PMID 23093163
- [15]Piccolo F, Pitman N, Bhatnagar R, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery Ann Am Thorac Soc, 2014.PMID 25296241
- [16]Wilshire CL, Jackson AS, Vallières E, et al. Effect of Intrapleural Fibrinolytic Therapy vs Surgery for Complicated Pleural Infections: A Randomized Clinical Trial JAMA Netw Open, 2023.PMID 37043201
- [17]Bartlett JG How important are anaerobic bacteria in aspiration pneumonia: when should they be treated and what is optimal therapy Infect Dis Clin North Am, 2013.PMID 23398871
- [18]Jain A, Patel A, Folch E, et al. Interventional techniques and strategies for postoperative bronchopleural fistula treatment: a narrative review J Thorac Dis, 2026.PMID 42583351
- [19]Lentz RJ, Lerner AD, Pannu JK, et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial Lancet Respir Med, 2019.PMID 30772283
- [20]Meumann EM, Cheng AC, Ward L, et al. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature Clin Infect Dis, 2012.PMID 22057702